A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Pfizer
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
GlaxoSmithKline
Pheon Therapeutics
Aesculap AG
GlaxoSmithKline
Orano Med LLC
Guardant Health, Inc.
RasCal Therapeutics, Inc.
Beijing Biotech
Xencor, Inc.
Cartography Biosciences
Pfizer
A2 Biotherapeutics Inc.
Arvinas Inc.
ALX Oncology Inc.
MBrace Therapeutics
New Phase Ltd.
Revolution Medicines, Inc.
GlaxoSmithKline
EXoPERT
Pfizer
Var2 Pharmaceuticals
Qilu Pharmaceutical Co., Ltd.
Natera, Inc.
Revolution Medicines, Inc.
Massive Bio, Inc.
Chongqing Precision Biotech Co., Ltd
Medigen Biotechnology Corporation
A2 Biotherapeutics Inc.
Epiliquid Holding, Inc
Revolution Medicines, Inc.
Mainz Biomed
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Sapience Therapeutics
Vyriad, Inc.
ADVANCED MARKER DISCOVERY S.L.
Natera, Inc.
Jiangsu Famous Medical Technology Co., Ltd.
Chongqing Precision Biotech Co., Ltd
Singlera Genomics Inc.
Aurigene Discovery Technologies Limited
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd